retatrutide investigational drug triple hormone receptor agonist Medscape | Retatrutide, Eli Lilly's first-in-class agonist, delivered meaningful weight loss at 80 weeks in all doses in the Retatrutide: A Triple Agonist Shaping

Current guidelines advise discontinuation before conception due to unknown teratogenic risks

The lower-dose 60mg version, Alli, is licensed for adults with a BMI of 28 or above and is intended for use for up to six months

Real or fake, here are the top 10 MMS scandals

Some Aetna benefit plans may exclude coverage of weight loss medications in their pharmacy benefit and/or health benefits plan

Becoming part of the Advanced Vitality team is something she is very passionate about because she is able to still help people achieve their personal health goals, all while having a more personable business to work for rather than a large hospital